Answers are grounded in this paper and cite their sources.
Background Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor dysfunction and is commonly treated with subthalamic nucleus deep brain stimulation (STN-DBS) in patients with advanced motor complications. Conventional continuous deep brain stimulation (cDBS) delivers uninterrupted stimulation, whereas adaptive deep brain stimulation (aDBS) adjusts stimulation according to physiological biomarkers or other signals. Although aDBS may improve motor control while reducing stimulation delivery, its comparative effectiveness and safety remain uncertain. Methods This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. PubMed, Embase, Scopus, and Cochrane CENTRAL were searched for eligible studies published between January 2013 and May 2026. Studies involving adults with idiopathic PD that compared aDBS with cDBS were included. The primary outcome was motor efficacy measured using Unified Parkinson's Disease Rating Scale (UPDRS) Part III or Movement Disorder Society-UPDRS Part III scores. Secondary outcomes included stimulation power and energy-related measures, stimulation ON-time, levodopa equivalent daily dose (LEDD), symptom-specific motor outcomes, gait and movement parameters, neurophysiological biomarkers, and safety. Compatible motor-outcome data were pooled using a random-effects model, and statistical heterogeneity was assessed using the I 2 statistic. Secondary outcomes were synthesized narratively when differences in outcome measures or reporting precluded quantitative pooling. Results Seven studies were included in the qualitative synthesis, and five eligible study datasets contributed to the primary motor-outcome meta-analysis. Compared with cDBS, aDBS was associated with a statistically significant difference favoring improved motor scores [mean difference (MD) −2.74 points, 95% confidence interval (CI) − 5.20 to − 0.29; p = 0.03 ], with substantial heterogeneity ( I 2 = 63% ). Sensitivity analysis restricted to four core crossover trials showed a similar direction of effect, although the difference was not statistically significant (MD −3.07 points, 95% CI − 6.27 to 0.13; p = 0.06; I 2 = 70% ). Individual studies reported lower stimulation power or reduced stimulation delivery with aDBS, while one retrospective cohort reported a numerically greater reduction in LEDD. Some studies also suggested potential benefits in rigidity, bradykinesia-related performance, and selected gait measures; however, these findings were based on small samples and heterogeneous outcome assessments. Neurophysiological findings indicated possible differences in beta-band activity, but their clinical significance remained uncertain. Safety reporting was limited, and the available evidence did not establish a comparative advantage for either stimulation approach. Conclusion aDBS was associated with a statistically significant pooled difference favoring improved motor outcomes compared with cDBS. However, substantial heterogeneity and the non-significant sensitivity analysis limit confidence in the robustness and generalizability of this finding. Although preliminary evidence suggests potential reductions in stimulation delivery and benefits in selected motor domains, comparative advantages in medication requirements and safety remain unestablished. Larger, adequately powered comparative trials with longer follow-up, standardized outcome measures, and systematic safety reporting are needed to clarify the clinical effectiveness and long-term safety of aDBS in patients with PD. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261388549 , identifier: CRD420261388549.
No takes yet. Share an insight, caveat, or question.
Hassan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: